These independent CME/CE activities are supported by an educational grant from Takeda Oncology.

Clinical Context:
Multiple Myeloma
  1. Course List
CME/CE Information

Target Audience

This series of activities is designed for hematologists, oncologists, radiologists, primary care physicians, internists, family practice practitioners, nurses, nurse practitioners, physician assistants, and pharmacists who treat patients with multiple myeloma.

Activity Goal

The goal of this program is to provide information and case studies at the point of care on current and emerging management strategies based on the most up-to-date evidence-based medicine and clinical trial results in multiple myeloma.

Learning Objective (s)

  • Describe the natural history of multiple myeloma, the importance of early diagnosis of this conidition, and recent advances in our understanding of pathophysiologic mechanisms that may serve as targets of therapy.
  • Evaluate criteria that have been developed to assess treatment response in multiple myeloma, delineate how these criteria can be used to risk-stratify patients in clinical practice, and consider therapeutic treatment options that improve patient outcomes.

CME Information: Physicians

Statement of Accreditation

Projects In Knowledge® is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation

Projects In Knowledge® designates this for a maximum of 11.0 AMA PRA Category 1 Credit(s). Physicians should claim only the credit commensurate with the extent of their participation in the activity.


To obtain credit:

  1. Read or listen to each activity carefully.
  2. Complete/submit each posttest and evaluation.
  3. Instantly access and print out your certificate.

There is no fee for this activity.


Projects In Knowledge has developed the contract to demonstrate our commitment to providing the highest quality professional education to clinicians, and to help clinicians set educational goals to challenge and enhance their learning experience.

For more information on the contract, click here.
Disclosure Information

The Disclosure Policy of Projects In Knowledge® requires that all those who have control of the content of CE activities comply with the ACCME’s Standards for Commercial Support regarding disclosure of relevant financial relationships. Faculty, planners, PIK editorial scientific team, reviewers, and medical writers are required to disclose any financial relationship they or their spouse/partner have with any ACCME-defined commercial interest* relevant to the content of this activity. Any discussions of unlabeled/unapproved uses of drugs or devices will also be disclosed during the presentations.

Kenneth C. Anderson, MD has received consulting fees from Celgene Corporation, Gilead Sciences, Millennium Pharmaceuticals, Onyx Pharmaceuticals, and Sanofi-Aventis; and has ownership interest in Acetylon Pharmaceuticals and OncoPep.

Sara Bringhen, MD, PhD has disclosed no significant relationships.

Shaji K. Kumar, MD

Jatin J. Shah, MD has received consulting fees from and has conducted contracted research for Array BioPharma, Celgene Corporation, Millennium Pharmaceuticals, Novartis Pharmaceuticals Corporation, and Onyx Pharmaceuticals.

Peer Reviewer has disclosed no relevant relationships.

Projects In Knowledge's staff members have no relevant relationships to disclose.

These activities may contain discussions of unlabeled/unapproved uses of drugs or devices. Specific product disclosure will be forthcoming in each activity.

The opinions expressed in these activities are those of the faculty and do not necessarily reflect those of Projects In Knowledge.

This activity is provided solely as an educational service. Specific patient care decisions are the responsibility of the clinician caring for the patient.

These independent CME/CE activities are supported by an educational grant from Takeda Oncology.

Projects In Knowledge is a registered trademark of Projects In Knowledge, Inc.